Autophagy Markers in Endometrial Polyps

Muğla Sıtkı Koçman University30 enrolled

Overview

The aim of this research is to evaluate autophagy markers in patients with endometrial polyps

Endometrial polyp are benign formations that are frequently encountered in gynecology practice and have malignant potential. It may be asymptomatic in the clinic or may present with abnormal uterine bleeding. Although its pathophysiology has not been clearly revealed, there are many studies in the literature about it. However, the autophagy pathway emerges as a subject that has never been evaluated. In this study, the investigators would like to prospectively evaluate Beclin 1, LC3A / B and p62 markers in the autophagy pathway in endometrial polyp tissue samples by immunohistochemistry and reveal their importance.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Endometrial Polyp Autophagy

Interventions

Beclin 1 geneGENETIC

The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.

Eligibility

Sex: FEMALEMin age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 35 years of age with a histopathologically confirmed diagnosis of endometrial polyp * patients over the age of 35 whose histopathologically reported normal endometrial biopsy results. Exclusion Criteria: * Are under the age of 35, * those with cognitive dysfunction, * diagnosed with any type of cancer * who are under treatment for cancer, * diabetes mellitus, * hypertension, * endometriosis, * adenomyosis, * chronic endometritis, * have an acute or chronic illness, * patients who have smoked and used alcohol in the last 10 years

Locations (1)

Mugla Sıtkı Kocman University Faculty of Medicine

Muğla, Turkey (Türkiye)

Outcomes

Primary Outcomes

autophagy marker

Beclin 1 gene level

Time frame: through study completion, an average of 1 year

autophagy marker

LC3II gene level

Time frame: through study completion, an average of 1 year

autophagy marker

p62 gene level

Time frame: through study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.